Ontology highlight
ABSTRACT:
SUBMITTER: Dufies M
PROVIDER: S-EPMC5625677 | biostudies-literature | 2017 Sep
REPOSITORIES: biostudies-literature
British journal of cancer 20170829 7
<h4>Background</h4>Sunitinib is one of the first-line standard treatments for metastatic clear cell renal cell carcinoma (ccRCC) with a median time to progression shorter than 1 year. The objective is to discover predictive markers of response to adapt the treatment at diagnosis.<h4>Methods</h4>Prospective phase 2 multi-centre trials were conducted in ccRCC patients initiating sunitinib (54 patients) or bevacizumab (45 patients) in the first-line metastatic setting (SUVEGIL and TORAVA trials). T ...[more]